{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:47:41Z","timestamp":1793717261711,"version":"4.6.1"},"reference-count":182,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-022-01905-4","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T03:27:16Z","timestamp":1661830036000},"page":"213-234","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Neuroendocrine neoplasms in the context of inherited tumor syndromes: a reappraisal focused on targeted therapies"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8899-684X","authenticated-orcid":false,"given":"R. M.","family":"Ruggeri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Benevento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"De Cicco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Fazzalari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Guadagno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Hasballa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. G.","family":"Tarsitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. M.","family":"Isidori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Colao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Faggiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of NIKE Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Aini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Albertelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Alessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Altieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Antonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Barrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Birtolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Campolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Cannavale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Cantone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Carra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Centello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Cozzolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Molfetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Vito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Fanciulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Feola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Ferra\u00f9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Giannetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Grillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Grossrubatscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Guarnotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Salvia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Laffi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Lania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Liccardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Malandrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Mazzilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Mikovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Minotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Modica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Muscogiuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Pandozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Pugliese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Puliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Ragni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Rubino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Sesti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Verde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Veresani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Vetrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Zamponi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Zanata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,30]]},"reference":[{"key":"1905_CR1","first-page":"817","volume":"35","author":"A Faggiano","year":"2008","unstructured":"Faggiano A, Ferolla P, Grimaldi F, Campana D, Manzoni M, Dav\u00ec MV et al (2008) Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data froma large prospective and retrospective Italian Epidemiological study: the net management study. J Endocrinol Invest 35:817\u2013823","journal-title":"J Endocrinol Invest"},{"key":"1905_CR2","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/BF03345602","volume":"31","author":"P Ferolla","year":"2008","unstructured":"Ferolla P, Faggiano A, Mansueto G, Avenia N, Cantelmi MG, Giovenali P et al (2008) The biological characterization of neuroendocrine tumors: the role of neuroendocrine markers. J Endocrinol Invest 31:277\u2013286","journal-title":"J Endocrinol Invest"},{"key":"1905_CR3","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.3390\/cancers13061247","volume":"13","author":"T Feola","year":"2021","unstructured":"Feola T, Centello R, Sesti F, Puliani G, Verrico M, Di Vito V, Di Gioia C, Bagni O, Lenzi A, Isidori AM, Giannetta E, Faggiano A (2021) Neuroendocrine carcinomas with atypical proliferation index and clinical behavior: a systematic review. Cancers 13:1247. https:\/\/doi.org\/10.3390\/cancers13061247","journal-title":"Cancers"},{"key":"1905_CR4","volume-title":"WHO classification of tumours of endocrine organs","author":"RV Lloyd","year":"2017","unstructured":"Lloyd RV, Osamura R, Kloppel G, Rosai J (2017) WHO classification of tumours of endocrine organs, 4th edn. IARC Press, Lyon","edition":"4"},{"key":"1905_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40618-022-01872-w","volume":"22","author":"R Modica","year":"2022","unstructured":"Modica R, Scandurra C, Maldonato NM, Dolce P, Dipietrangelo GG, Centello R, Di Vito V, Giannetta E, Isidori AM, Lenzi A, Faggiano A, Colao A (2022) Health-related quality of life in patients with neuroendocrine neoplasms: a two-wave longitudinal study. J Endocrinol Invest 22:1\u20138. https:\/\/doi.org\/10.1007\/s40618-022-01872-w","journal-title":"J Endocrinol Invest"},{"key":"1905_CR6","doi-asserted-by":"publisher","first-page":"e316","DOI":"10.1210\/clinem\/dgaa7602021;106(1)","volume":"106","author":"C Scandurra","year":"2021","unstructured":"Scandurra C, Modica R, Maldonato NM, Dolce P, Dipietrangelo GG, Centello R, di Vito V, Bottiglieri F, de Cicco F, Giannetta E, Isidori AM, Lenzi A, Muzii B, Faggiano A, Colao A (2021) Quality of life in patients with neuroendocrine neoplasms: the role of severity, clinical heterogeneity, and resilience. J Clin Endocrinol Metab 106:e316\u2013e327. https:\/\/doi.org\/10.1210\/clinem\/dgaa7602021;106(1)","journal-title":"J Clin Endocrinol Metab"},{"key":"1905_CR7","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.3390\/jcm11143983","volume":"11","author":"V Zamponi","year":"2022","unstructured":"Zamponi V, La Salvia A, Tarsitano MG, Mikovic N, Rinzivillo M, Panzuto F, Giannetta E, Faggiano A, Mazzilli R (2022) Effect of neuroendocrine neoplasm treatment on human reproductive health and sexual function. J Clin Med 11:3983. https:\/\/doi.org\/10.3390\/jcm11143983","journal-title":"J Clin Med"},{"key":"1905_CR8","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.annpat.2020.01.002","volume":"40","author":"A Couvelard","year":"2020","unstructured":"Couvelard A, Scoazec JY (2020) Inherited tumor syndromes of gastroenteropancreatic and thoracic neuroendocrine neoplasms. Ann Pathol 40:120\u2013133. https:\/\/doi.org\/10.1016\/j.annpat.2020.01.002","journal-title":"Ann Pathol"},{"key":"1905_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103648","volume":"172","author":"H Ishida","year":"2022","unstructured":"Ishida H, Lam AK (2022) Pancreatic neuroendocrine neoplasms: updates on genomic changes in inherited tumour syndromes and sporadic tumours based on WHO classification. Crit Rev Oncol Hematol 172:103648. https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103648","journal-title":"Crit Rev Oncol Hematol"},{"key":"1905_CR10","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.3390\/cancers13071701","volume":"13","author":"A La Salvia","year":"2021","unstructured":"La Salvia A, Espinosa-Olarte P, Riesco-Martinez MDC, Anton-Pascual B, Garcia-Carbonero R (2021) Targeted cancer therapy: what\u2019s new in the field of neuroendocrine neoplasms? Cancers (Basel) 13:1701. https:\/\/doi.org\/10.3390\/cancers13071701","journal-title":"Cancers (Basel)"},{"key":"1905_CR11","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","volume":"27","author":"A Rinke","year":"2009","unstructured":"Rinke A, M\u00fcller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bl\u00e4ker M, Harder J, Arnold C, Gress T, Arnold R, PROMID Study Group (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27:4656\u20134563. https:\/\/doi.org\/10.1200\/JCO.2009.22.8510","journal-title":"J Clin Oncol"},{"key":"1905_CR12","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s40618-017-0692-0","volume":"40","author":"M Albertelli","year":"2017","unstructured":"Albertelli M, Nazzari E, Sciallero S, Grillo F, Morbelli S, De Cian F, Cittadini G, Ambrosetti E, Ciarmiello A, Ferone D, IRCCS Policlinico San Martino, University of Genova Neuroendocrine Tumor Board (2017) Anti-tumoral effects of somatostatin analogs: a lesson from the CLARINET study. J Endocrinol Invest 40:1265\u20131269. https:\/\/doi.org\/10.1007\/s40618-017-0692-0","journal-title":"J Endocrinol Invest"},{"key":"1905_CR13","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1159\/000475526","volume":"105","author":"RJ Hicks","year":"2017","unstructured":"Hicks RJ, Kwekkeboom DJ, Krenning E, Bodei L, Grozinsky-Glasberg S, Arnold R et al (2017) ENETS consensus guidelines for the standards of care in neuroendocrine neoplasia: peptide receptor radionuclide therapy with radiolabeled somatostatin analogues. Neuroendocrinology 105:295\u2013309. https:\/\/doi.org\/10.1159\/000475526","journal-title":"Neuroendocrinology"},{"key":"1905_CR14","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1056\/NEJMoa1003825","volume":"364","author":"E Raymond","year":"2011","unstructured":"Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C et al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501\u2013513. https:\/\/doi.org\/10.1056\/NEJMoa1003825 (Erratum in: N Engl J Med 364:1082)","journal-title":"N Engl J Med"},{"key":"1905_CR15","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1009290","volume":"364","author":"JC Yao","year":"2011","unstructured":"Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514\u2013523. https:\/\/doi.org\/10.1056\/NEJMoa1009290","journal-title":"N Engl J Med"},{"key":"1905_CR16","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","volume":"387","author":"JC Yao","year":"2016","unstructured":"Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E et al (2016) Everolimus for the treatment of advanced, nonfunctional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study HHS Public Access. Lancet 387:968\u2013977","journal-title":"Lancet"},{"key":"1905_CR17","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.beem.2010.07.003","volume":"24","author":"RV Thakker","year":"2010","unstructured":"Thakker RV (2010) Multiple endocrine neoplasia type 1 (MEN1). Best Pract Res Clin Endocrinol Metab 24:355\u2013370. https:\/\/doi.org\/10.1016\/j.beem.2010.07.003","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"1905_CR18","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/705036","author":"C Romei","year":"2012","unstructured":"Romei C, Pardi E, Cetani F, Elisei R (2012) Genetic and clinical features of multiple endocrine neoplasia types 1 and 2. J Oncol. https:\/\/doi.org\/10.1155\/2012\/705036","journal-title":"J Oncol"},{"key":"1905_CR19","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1210\/jc.2012-1230","volume":"97","author":"RV Thakker","year":"2012","unstructured":"Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, Melmed S, Sakurai A, Tonelli F, Brandi ML, Endocrine Society (2012) Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 97:2990\u20133011. https:\/\/doi.org\/10.1210\/jc.2012-1230","journal-title":"J Clin Endocrinol Metab"},{"key":"1905_CR20","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1210\/jc.2014-3659","volume":"100","author":"P Goudet","year":"2015","unstructured":"Goudet P, Dalac A, Le Bras M, Cardot-Bauters C, Niccoli P, L\u00e9vy-Bohbot N et al (2015) MEN1 disease occurring before 21 years old: a 160-patient cohort study from the Groupe d\u2019\u00e9tude des Tumeurs Endocrines. J Clin Endocrinol Metab 100:1568\u20131577. https:\/\/doi.org\/10.1210\/jc.2014-3659","journal-title":"J Clin Endocrinol Metab"},{"key":"1905_CR21","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s12020-017-1234-4","volume":"58","author":"F Giusti","year":"2017","unstructured":"Giusti F, Cianferotti L, Boaretto F, Cetani F, Cioppi F, Colao A et al (2017) Multiple endocrine neoplasia syndrome type 1: institution, management, and data analysis of a nationwide multicenter patient database. Endocrine 58:349\u2013359. https:\/\/doi.org\/10.1007\/s12020-017-1234-4","journal-title":"Endocrine"},{"key":"1905_CR22","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1056\/NEJMc1406028","volume":"371","author":"KM Dreijerink","year":"2014","unstructured":"Dreijerink KM, Goudet P, Burgess JR, Valk GD, International Breast Cancer in MEN1 Study Group (2014) Breast-cancer predisposition in multiple endocrine neoplasia type 1. N Engl J Med 371:583\u2013584. https:\/\/doi.org\/10.1056\/NEJMc1406028","journal-title":"N Engl J Med"},{"key":"1905_CR23","doi-asserted-by":"publisher","first-page":"T53","DOI":"10.1530\/ERC-20-0018","volume":"27","author":"ND Perrier","year":"2020","unstructured":"Perrier ND, Arnold A, Costa-Guda J, Busaidy NL, Nguyen H, Chuang HH, Brandi ML (2020) Hereditary endocrine tumours: current state-of-the-art and research opportunities: new and future perspectives for parathyroid carcinoma. Endocr Relat Cancer 27:T53\u2013T63. https:\/\/doi.org\/10.1530\/ERC-20-0018","journal-title":"Endocr Relat Cancer"},{"key":"1905_CR24","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1210\/jc.2018-01170","volume":"104","author":"P Romanet","year":"2019","unstructured":"Romanet P, Mohamed A, Giraud S, Odou MF, North MO, Pertuit M, Pasmant E, Coppin L, Guien C, Calender A, Borson-Chazot F, B\u00e9roud C, Goudet P, Barlier A (2019) UMD-MEN1 database: an overview of the 370 MEN1 variants present in 1676 patients from the French population. J Clin Endocrinol Metab 104:753\u2013764. https:\/\/doi.org\/10.1210\/jc.2018-01170","journal-title":"J Clin Endocrinol Metab"},{"key":"1905_CR25","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/332085a0","volume":"332","author":"C Larsson","year":"1988","unstructured":"Larsson C, Skogseid B, \u00d6berg K, Nakamura Y, Nordenskj\u00f6ld M (1988) Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 332:85\u201387. https:\/\/doi.org\/10.1038\/332085a0","journal-title":"Nature"},{"key":"1905_CR26","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1056\/NEJM198907273210403","volume":"321","author":"RV Thakker","year":"1989","unstructured":"Thakker RV, Bouloux P, Wooding C, Chotai K, Broad PM, Spurr NK, Besser GM, O\u2019Riordan JL (1989) Association of parathyroid tumors in multiple endocrine neoplasia type 1 with loss of alleles on chromosome 11. N Engl J Med 321:218\u2013224. https:\/\/doi.org\/10.1056\/NEJM198907273210403","journal-title":"N Engl J Med"},{"key":"1905_CR27","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1086\/301729","volume":"62","author":"JH Bassett","year":"1998","unstructured":"Bassett JH, Forbes SA, Pannett AA, Lloyd SE, Christie PT, Wooding C, Harding B, Besser GM, Edwards CR, Monson JP, Sampson J, Wass JA, Wheeler MH, Thakker RV (1998) Characterization of mutations in patients with multiple endocrine neoplasia type 1. Am J Hum Genet 62:232\u2013244. https:\/\/doi.org\/10.1086\/301729","journal-title":"Am J Hum Genet"},{"key":"1905_CR28","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/humu.20605","volume":"29","author":"MC Lemos","year":"2008","unstructured":"Lemos MC, Thakker RV (2008) Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum Mutat 29:22\u201332. https:\/\/doi.org\/10.1002\/humu.20605","journal-title":"Hum Mutat"},{"key":"1905_CR29","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/j.1365-2265.2007.02934.x","volume":"67","author":"A Machens","year":"2007","unstructured":"Machens A, Schaaf L, Karges W, Frank-Raue K, Bartsch DK, Rothmund M, Schneyer U, Goretzki P, Raue F, Dralle H (2007) Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicentre study of 258 gene carriers. Clin Endocrinol (Oxf) 67:613\u2013622. https:\/\/doi.org\/10.1111\/j.1365-2265.2007.02934.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1905_CR30","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s00268-009-9980-y","volume":"33","author":"P Goudet","year":"2009","unstructured":"Goudet P, Murat A, Cardot-Bauters C, Emy P, Baudin E, du Boullay CH et al (2009) Thymic neuroendocrine tumors in multiple endocrine neoplasia type 1: a comparative study on 21 cases among a series of 761 MEN1 from the GTE (Groupe des Tumeurs Endocrines). World J Surg 33:1197\u20131207. https:\/\/doi.org\/10.1007\/s00268-009-9980-y","journal-title":"World J Surg"},{"key":"1905_CR31","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.surg.2017.04.044","volume":"163","author":"I Christakis","year":"2018","unstructured":"Christakis I, Qiu W, Hyde SM, Cote GJ, Grubbs EG, Perrier ND, Lee JE (2018) Genotype-phenotype pancreatic neuroendocrine tumor relationship in multiple endocrine neoplasia type 1 patients: a 23-year experience at a single institution. Surgery 163:212\u2013217. https:\/\/doi.org\/10.1016\/j.surg.2017.04.044","journal-title":"Surgery"},{"key":"1905_CR32","volume-title":"Harrison's principles of internal medicine","author":"RT Jensen","year":"2018","unstructured":"Jensen RT (2018) Neuroendocrine tumors of the gastrointestinal tract and pancreas. In: Jameson J, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J (eds) Harrison\u2019s principles of internal medicine, 20th edn. McGraw Hill","edition":"20"},{"key":"1905_CR33","doi-asserted-by":"publisher","first-page":"665698","DOI":"10.3389\/fendo.2021.665698","volume":"12","author":"E Giannetta","year":"2021","unstructured":"Giannetta E, Sesti F, Modica R, Grossrubatscher EM, Guarnotta V, Ragni A, Zanata I, Colao A, Faggiano A (2021) Case report: unmasking hypercalcemia in patients with neuroendocrine neoplasms experience from six Italian Referral Centers. Front Endocrinol (Lausanne) 12:665698. https:\/\/doi.org\/10.3389\/fendo.2021.665698","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1905_CR34","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s11154-020-09547-8","volume":"21","author":"G Fanciulli","year":"2020","unstructured":"Fanciulli G, Ruggeri RM, Grossrubatscher E, Calzo FL, Wood TD, Faggiano A, Isidori A, Colao A, NIKE (2020) Serotonin pathway in carcinoid syndrome: clinical, diagnostic, prognostic and therapeutic implications. Rev Endocr Metab Disord 21:599\u2013612. https:\/\/doi.org\/10.1007\/s11154-020-09547-8","journal-title":"Rev Endocr Metab Disord"},{"key":"1905_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.6779832021","volume":"11","author":"F Sesti","year":"2021","unstructured":"Sesti F, Feola T, Puliani G, Centello R, Di Vito V, Bagni O, Lenzi A, Isidori AM, Cantisani V, Faggiano A, Giannetta E (2021) Sunitinib treatment for advanced paraganglioma: case report of a novel SDHD gene mutation variant and systematic review of the literature. Front Oncol 11:677983. https:\/\/doi.org\/10.3389\/fonc.2021.6779832021","journal-title":"Front Oncol"},{"issue":"4","key":"1905_CR36","doi-asserted-by":"publisher","first-page":"R147","DOI":"10.1530\/EJE-13-1012014","volume":"170","author":"P Iglesias","year":"2014","unstructured":"Iglesias P, D\u00edez JJ (2014) Management of endocrine disease: a clinical update on tumor-induced hypoglycemia. Eur J Endocrinol 170(4):R147\u2013R157. https:\/\/doi.org\/10.1530\/EJE-13-1012014","journal-title":"Eur J Endocrinol"},{"key":"1905_CR37","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.beem.2006.12.004","volume":"21","author":"G \u00c5kerstr\u00f6m","year":"2007","unstructured":"\u00c5kerstr\u00f6m G, Hellman P (2007) Surgery on neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 21:87\u2013109. https:\/\/doi.org\/10.1016\/j.beem.2006.12.004","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"1905_CR38","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S2213-8587(15)00043-1","volume":"3","author":"CJ Yates","year":"2015","unstructured":"Yates CJ, Newey PJ, Thakker RV (2015) Challenges and controversies in management of pancreatic neuroendocrine tumours in patients with MEN1. Lancet Diabetes Endocrinol 3:895\u2013905. https:\/\/doi.org\/10.1016\/S2213-8587(15)00043-1","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1905_CR39","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s12020-020-02217-4","volume":"68","author":"K Oleinikov","year":"2020","unstructured":"Oleinikov K, Uri I, Jacob H, Epshtein J, Benson A, Ben-Haim S et al (2020) Long-term outcomes in MEN-1 patients with pancreatic neuroendocrine neoplasms: an Israeli specialist center experience. Endocrine 68:222\u2013229. https:\/\/doi.org\/10.1007\/s12020-020-02217-4","journal-title":"Endocrine"},{"key":"1905_CR40","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1080\/14737140.2019.1693893","volume":"19","author":"L Lee","year":"2019","unstructured":"Lee L, Ito T (2019) Jensen RT (2019) Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies. Expert Rev Anticancer Ther 19:1029\u20131050. https:\/\/doi.org\/10.1080\/14737140.2019.1693893","journal-title":"Expert Rev Anticancer Ther"},{"key":"1905_CR41","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1677\/ERC-07-0288","volume":"15","author":"S Grozinsky-Glasberg","year":"2008","unstructured":"Grozinsky-Glasberg S, Shimon I, Korbonits M, Grossman AB (2008) Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms. Endocr Relat Cancer 15:701\u2013720. https:\/\/doi.org\/10.1677\/ERC-07-0288","journal-title":"Endocr Relat Cancer"},{"issue":"1039","key":"1905_CR42","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.3390\/ph14101039","volume":"14","author":"A La Salvia","year":"2021","unstructured":"La Salvia A, Sesti F, Grinzato C, Mazzilli R, Tarsitano MG, Giannetta E, Faggiano A (2021) Somatostatin analogue therapy in MEN1-related pancreatic neuroendocrine tumors from evidence to clinical practice: a systematic review. Pharmaceuticals (Basel) 14(1039):2021. https:\/\/doi.org\/10.3390\/ph14101039","journal-title":"Pharmaceuticals (Basel)"},{"key":"1905_CR43","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/cen.12411.80(6)","volume":"80","author":"V Ramundo","year":"2014","unstructured":"Ramundo V, Del Prete M, Marotta V, Marciello F, Camera L, Napolitano V, De Luca L, Circelli L, Colantuoni V, Di Sarno A, Carrat\u00f9 AC, de Luca-di-Roseto C, Colao A, Faggiano A, Multidisciplinary Group for Neuroendocrine Tumors of Naples (2014) Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours. Clin Endocrinol (Oxf) 80:850\u2013855. https:\/\/doi.org\/10.1111\/cen.12411.80(6)","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"1905_CR44","doi-asserted-by":"publisher","first-page":"dgz007","DOI":"10.1210\/clinem\/dgz0072019;105(1)","volume":"105","author":"A Faggiano","year":"2020","unstructured":"Faggiano A, Modica R, Lo-Calzo F, Camera L, Napolitano V, Altieri B, de Cicco F, Bottiglieri F, Sesti F, Badalamenti G, Isidori AM, Colao A (2020) Lanreotide Therapy vs active surveillance in MEN1-related pancreatic neuroendocrine tumors < 2 centimeters. J Clin Endocrinol Metab 105(1):dgz007. https:\/\/doi.org\/10.1210\/clinem\/dgz0072019;105(1)","journal-title":"J Clin Endocrinol Metab"},{"key":"1905_CR45","doi-asserted-by":"publisher","first-page":"645","DOI":"10.21037\/jgo.2019.01.33.10(4)","volume":"10","author":"JE Nu\u00f1ez","year":"2019","unstructured":"Nu\u00f1ez JE, Donadio M, Filho DR, Rego JF, Barros M, Formiga MN, Lopez R, Riechelmann R (2019) The efficacy of everolimus and sunitinib in patients with sporadic or germline mutated metastatic pancreatic neuroendocrine tumors. J Gastrointest Oncol 10:645\u2013651. https:\/\/doi.org\/10.21037\/jgo.2019.01.33.10(4)","journal-title":"J Gastrointest Oncol"},{"key":"1905_CR46","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1200\/JCO.2009.24.2669","volume":"28","author":"JC Yao","year":"2010","unstructured":"Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P et al (2010) Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 28:69\u201376. https:\/\/doi.org\/10.1200\/JCO.2009.24.2669","journal-title":"J Clin Oncol"},{"key":"1905_CR47","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1158\/1535-7163.MCT-17-1204","volume":"17","author":"CE Chamberlain","year":"2018","unstructured":"Chamberlain CE, German MS, Yang K, Wang J, VanBrocklin H, Regan M et al (2018) A patient-derived xenograft model of pancreatic neuroendocrine tumors identifies sapanisertib as a possible new treatment for everolimus-resistant tumors. Mol Cancer Ther 17:2702\u20132709. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-1204","journal-title":"Mol Cancer Ther"},{"key":"1905_CR48","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1016\/j.ajpath.2013.02.023","volume":"182","author":"X Chu","year":"2013","unstructured":"Chu X, Gao X, Jansson L, Quach M, Skogseid B, Barbu A (2013) Multiple microvascular alterations in pancreatic islets and neuroendocrine tumors of a Men1 mouse model. Am J Pathol 182:2355\u20132367. https:\/\/doi.org\/10.1016\/j.ajpath.2013.02.023","journal-title":"Am J Pathol"},{"key":"1905_CR49","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.mce.2013.08.002","volume":"386","author":"RV Thakker","year":"2014","unstructured":"Thakker RV (2014) Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). Mol Cell Endocrinol 386:2\u201315. https:\/\/doi.org\/10.1016\/j.mce.2013.08.002","journal-title":"Mol Cell Endocrinol"},{"key":"1905_CR50","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nrc2347.2008","volume":"8","author":"IM Chu","year":"2008","unstructured":"Chu IM, Hengst L, Slingerland JM (2008) The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 8:253\u2013267. https:\/\/doi.org\/10.1038\/nrc2347.2008","journal-title":"Nat Rev Cancer"},{"key":"1905_CR51","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s40618-017-0783-y","volume":"41","author":"EB Conemans","year":"2018","unstructured":"Conemans EB, Raicu-Ionita GM, Pieterman CRC, Dreijerink KMA, Dekkers OM, Hermus AR et al (2018) Expression of p27Kip1 and p18Ink4c in human multiple endocrine neoplasia type 1-related pancreatic neuroendocrine tumors. J Endocrinol Invest 41:655\u2013661. https:\/\/doi.org\/10.1007\/s40618-017-0783-y","journal-title":"J Endocrinol Invest"},{"key":"1905_CR52","doi-asserted-by":"publisher","first-page":"15558","DOI":"10.1073\/pnas.060387710303","volume":"103","author":"NS Pellegata","year":"2006","unstructured":"Pellegata NS, Quintanilla-Martinez L, Siggelkow H, Samson E, Bink K, H\u00f6fler H, Fend F, Graw J, Atkinson MJ (2006) Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci U S A 103:15558\u201315563. https:\/\/doi.org\/10.1073\/pnas.060387710303","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1905_CR53","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1159\/000345670","volume":"41","author":"M Lee","year":"2013","unstructured":"Lee M, Pellegata NS (2013) Multiple endocrine neoplasia type 4. Front Horm Res 41:63\u201378. https:\/\/doi.org\/10.1159\/000345670","journal-title":"Front Horm Res"},{"key":"1905_CR54","unstructured":"de Herder WW, Hofland J (2022) Multiple endocrine neoplasia type 4. In: Feingold KR, Anawalt B, Boyce A, et al. (eds) Endotext. South Dartmouth (MA): MDText.com, Inc.; 2000. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK568728\/"},{"key":"1905_CR55","doi-asserted-by":"publisher","first-page":"3637","DOI":"10.1210\/jc.2019-00082","volume":"104","author":"A Frederiksen","year":"2019","unstructured":"Frederiksen A, Rossing M, Hermann P, Ejersted C, Thakker RV, Frost M (2019) Clinical features of multiple endocrine neoplasia type 4: novel pathogenic variant and review of published cases. J Clin Endocrinol Metab 104:3637\u20133646. https:\/\/doi.org\/10.1210\/jc.2019-00082","journal-title":"J Clin Endocrinol Metab"},{"key":"1905_CR56","doi-asserted-by":"publisher","first-page":"T195","DOI":"10.1530\/ERC-17-0243","volume":"24","author":"R Alrezk","year":"2017","unstructured":"Alrezk R, Hannah-Shmouni F, Stratakis CA (2017) MEN4 and CDKN1B mutations: the latest of the MEN syndromes. Endocr Relat Cancer 24:T195\u2013T208. https:\/\/doi.org\/10.1530\/ERC-17-0243","journal-title":"Endocr Relat Cancer"},{"key":"1905_CR57","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s40618-021-01705-2","volume":"45","author":"V Andreasi","year":"2022","unstructured":"Andreasi V, Ricci C, Partelli S, Guarneri G, Ingaldi C, Muffatti F, Crippa S, Casadei R, Falconi M (2022) Predictors of disease recurrence after curative surgery for nonfunctioning pancreatic neuroendocrine neoplasms (NF-PanNENs): a systematic review and meta-analysis. J Endocrinol Invest 45:705\u2013718. https:\/\/doi.org\/10.1007\/s40618-021-01705-2","journal-title":"J Endocrinol Invest"},{"key":"1905_CR58","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1111\/cas.12246","volume":"104","author":"LC Ooi","year":"2013","unstructured":"Ooi LC, Watanabe N, Futamura Y, Sulaiman SF, Darah I, Osada H (2013) Identification of small molecule inhibitors of p27(Kip1) ubiquitination by high-throughput screening. Cancer Sci 104:1461\u20131467. https:\/\/doi.org\/10.1111\/cas.12246","journal-title":"Cancer Sci"},{"key":"1905_CR59","doi-asserted-by":"publisher","first-page":"225","DOI":"10.15403\/jgld.2014.1121.242.skp2","volume":"24","author":"OV Bochis","year":"2015","unstructured":"Bochis OV, Irimie A, Pichler M, Berindan-Neagoe I (2015) The role of Skp2 and its substrate CDKN1B (p27) in colorectal cancer. J Gastrointestin Liver Dis 24:225\u2013234. https:\/\/doi.org\/10.15403\/jgld.2014.1121.242.skp2","journal-title":"J Gastrointestin Liver Dis"},{"key":"1905_CR60","doi-asserted-by":"publisher","first-page":"474","DOI":"10.2741\/4320","volume":"20","author":"Z Hao","year":"2015","unstructured":"Hao Z, Huang S (2015) E3 ubiquitin ligase Skp2 as an attractive target in cancer therapy. Front Biosci (Landmark Ed) 20:474\u2013490. https:\/\/doi.org\/10.2741\/4320","journal-title":"Front Biosci (Landmark Ed)"},{"key":"1905_CR61","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1126\/science.8493574","volume":"260","author":"F Latif","year":"1993","unstructured":"Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML et al (1993) Identification of the von Hippel\u2013Lindau disease tumor suppressor gene. Science 260:1317\u20131320. https:\/\/doi.org\/10.1126\/science.8493574","journal-title":"Science"},{"key":"1905_CR62","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/nrc2502","volume":"8","author":"WG Kaelin","year":"2008","unstructured":"Kaelin WG (2008) The von Hippel\u2013Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer 8:865\u2013873. https:\/\/doi.org\/10.1038\/nrc2502","journal-title":"Nat Rev Cancer"},{"key":"1905_CR63","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1016\/j.ejca.2013.02.024","volume":"49","author":"IJ Frew","year":"2013","unstructured":"Frew IJ, Smole Z, Thoma CR, Krek W (2013) Genetic deletion of the long isoform of the von Hippel\u2013Lindau tumour suppressor gene product alters microtubule dynamics. Eur J Cancer 49:2433\u20132440. https:\/\/doi.org\/10.1016\/j.ejca.2013.02.024","journal-title":"Eur J Cancer"},{"key":"1905_CR64","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1159\/000369362","volume":"37","author":"S Schmid","year":"2014","unstructured":"Schmid S, Gillessen S, Binet I, Br\u00e4ndle M, Engeler D, Greiner J et al (2014) Management of von Hippel\u2013Lindau disease: an interdisciplinary review. Oncol Res Treat 37:761\u2013771. https:\/\/doi.org\/10.1159\/000369362","journal-title":"Oncol Res Treat"},{"key":"1905_CR65","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40618-017-0683-1","volume":"41","author":"J Crespigio","year":"2018","unstructured":"Crespigio J, Berbel LCL, Dias MA, Berbel RF, Pereira SS, Pignatelli D, Mazzuco TL (2018) Von Hippel\u2013Lindau disease: a single gene, several hereditary tumors. J Endocrinol Invest 41:21\u201331. https:\/\/doi.org\/10.1007\/s40618-017-0683-1","journal-title":"J Endocrinol Invest"},{"key":"1905_CR66","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/ejhg.2010.175.2011","volume":"19","author":"ER Maher","year":"2011","unstructured":"Maher ER, Neumann HP, Richard S (2011) von Hippel\u2013Lindau disease: a clinical and scientific review. Eur J Hum Genet 19:617\u2013623. https:\/\/doi.org\/10.1038\/ejhg.2010.175.2011","journal-title":"Eur J Hum Genet"},{"key":"1905_CR67","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/s0039-6257(01)00245-4","volume":"46","author":"AD Singh","year":"2001","unstructured":"Singh AD, Shields CL, Shields JA (2001) Von Hippel\u2013Lindau disease. Surv Ophthalmol 46:117\u2013142. https:\/\/doi.org\/10.1016\/s0039-6257(01)00245-4","journal-title":"Surv Ophthalmol"},{"key":"1905_CR68","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S0002-9440(10)65563-0","volume":"153","author":"IA Lubensky","year":"1998","unstructured":"Lubensky IA, Pack S, Ault D, Vortmeyer AO, Libutti SK, Choyke PL, Walther MM, Linehan WM, Zhuang Z (1998) Multiple neuroendocrine tumors of the pancreas in von Hippel\u2013Lindau disease patients: histopathological and molecular genetic analysis. Am J Pathol 153:223\u2013231. https:\/\/doi.org\/10.1016\/S0002-9440(10)65563-0","journal-title":"Am J Pathol"},{"key":"1905_CR69","unstructured":"Gl\u00e4sker S, Neumann HPH, Koch CA, et al. (2018) Von Hippel\u2013Lindau disease. In: Feingold KR, Anawalt B, Boyce A, et al. (eds) Endotext. South Dartmouth (MA): MDText.com, Inc.; 2000. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK279124\/"},{"key":"1905_CR70","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(03)13643-4","volume":"361","author":"RR Lonser","year":"2003","unstructured":"Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, Oldfield EH (2003) von Hippel\u2013Lindau disease. Lancet 361:2059\u20132067. https:\/\/doi.org\/10.1016\/S0140-6736(03)13643-4","journal-title":"Lancet"},{"key":"1905_CR71","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1007\/s11605-012-1847-0","volume":"16","author":"M Charlesworth","year":"2012","unstructured":"Charlesworth M, Verbeke CS, Falk GA, Walsh M, Smith AM, Morris-Stiff G (2012) Pancreatic lesions in von Hippel\u2013Lindau disease? A systematic review and meta-synthesis of the literature. J Gastrointest Surg 16:1422\u20131428. https:\/\/doi.org\/10.1007\/s11605-012-1847-0","journal-title":"J Gastrointest Surg"},{"issue":"2","key":"1905_CR72","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1097\/SLA.0000000000000856","volume":"262","author":"L de Mestier","year":"2015","unstructured":"de Mestier L, Gaujoux S, Cros J, Hentic O, Vullierme MP, Couvelard A, Cadiot G, Sauvanet A, Ruszniewski P, Richard S, Hammel P (2015) Long-term prognosis of resected pancreatic neuroendocrine tumors in von Hippel\u2013Lindau disease is favorable and not influenced by small tumors left in place. Ann Surg 262(2):384\u2013388. https:\/\/doi.org\/10.1097\/SLA.0000000000000856","journal-title":"Ann Surg"},{"key":"1905_CR73","doi-asserted-by":"publisher","first-page":"20","DOI":"10.15586\/jkcvhl.2017.88","volume":"4","author":"N Varshney","year":"2017","unstructured":"Varshney N, Kebede AA, Owusu-Dapaah H, Lather J, Kaushik M, Bhullar JS (2017) A review of Von Hippel\u2013Lindau syndrome. J Kidney Cancer VHL 4:20\u201329. https:\/\/doi.org\/10.15586\/jkcvhl.2017.88","journal-title":"J Kidney Cancer VHL"},{"key":"1905_CR74","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1530\/ERC-18-0100","volume":"25","author":"T Krauss","year":"2018","unstructured":"Krauss T, Ferrara AM, Links TP, Wellner U, Bancos I, Kvachenyuk A et al (2018) Preventive medicine of von Hippel\u2013Lindau disease-associated pancreatic neuroendocrine tumors. Endocr Relat Cancer 25:783\u2013793. https:\/\/doi.org\/10.1530\/ERC-18-0100","journal-title":"Endocr Relat Cancer"},{"key":"1905_CR75","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1001\/jamaoncol.2017.3428.2018","volume":"4","author":"A Tirosh","year":"2018","unstructured":"Tirosh A, Sadowski SM, Linehan WM, Libutti SK, Patel D, Nilubol N, Kebebew E (2018) Association of VHL genotype with pancreatic neuroendocrine tumor phenotype in patients with von Hippel\u2013Lindau disease. JAMA Oncol 4:124\u2013126. https:\/\/doi.org\/10.1001\/jamaoncol.2017.3428.2018","journal-title":"JAMA Oncol"},{"key":"1905_CR76","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s12672-013-0134-1","volume":"4","author":"AB Weisbrod","year":"2013","unstructured":"Weisbrod AB, Zhang L, Jain M, Barak S, Quezado MM, Kebebew E (2013) Altered PTEN, ATRX, CHGA, CHGB, and TP53 expression are associated with aggressive VHL-associated pancreatic neuroendocrine tumors. Horm Cancer 4:165\u2013175. https:\/\/doi.org\/10.1007\/s12672-013-0134-1","journal-title":"Horm Cancer"},{"key":"1905_CR77","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1245\/s10434-012-2276-8","volume":"19","author":"AB Weisbrod","year":"2012","unstructured":"Weisbrod AB, Liewehr DJ, Steinberg SM, Patterson EE, Libutti SK, Linehan WM, Nilubol N, Kebebew E (2012) Association of type o blood with pancreatic neuroendocrine tumors in von Hippel\u2013Lindau syndrome. Ann Surg Oncol 19:2054\u20132059. https:\/\/doi.org\/10.1245\/s10434-012-2276-8","journal-title":"Ann Surg Oncol"},{"key":"1905_CR78","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.surg.2007.09.012","volume":"142","author":"JA Blansfield","year":"2007","unstructured":"Blansfield JA, Choyke L, Morita SY, Choyke PL, Pingpank JF, Alexander HR, Seidel G, Shutack Y, Yuldasheva N, Eugeni M, Bartlett DL, Glenn GM, Middelton L, Linehan WM, Libutti SK (2007) Clinical, genetic and radiographic analysis of 108 patients with von Hippel\u2013Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Surgery 142:814\u2013818. https:\/\/doi.org\/10.1016\/j.surg.2007.09.012","journal-title":"Surgery"},{"key":"1905_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2022.104538","volume":"65","author":"M Louise","year":"2022","unstructured":"Louise M, Binderup M, Smerdel M, Borgwadt L, Beck Nielsen SS, Madsen MG, M\u00f8ller HU et al (2022) von Hippel\u2013Lindau disease: updated guideline for diagnosis and surveillance. Eur J Med Genet 65:104538. https:\/\/doi.org\/10.1016\/j.ejmg.2022.104538","journal-title":"Eur J Med Genet"},{"key":"1905_CR80","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1210\/jc.2008-1972","volume":"94","author":"C Jimenez","year":"2009","unstructured":"Jimenez C, Cabanillas ME, Santarpia L, Jonasch E, Kyle KL, Lano EA, Matin SF, Nunez RF, Perrier ND, Phan A, Rich TA, Shah B, Williams MD, Waguespack SG (2009) Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel\u2013Lindau disease-related tumors. J Clin Endocrinol Metab 94:386\u2013391. https:\/\/doi.org\/10.1210\/jc.2008-1972","journal-title":"J Clin Endocrinol Metab"},{"key":"1905_CR81","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1097\/MPA.0b013e31822a645e","volume":"41","author":"T Ali","year":"2012","unstructured":"Ali T, Kandil D, Piperdi B (2012) Long-term disease control with sunitinib in a patient with metastatic pancreatic neuroendocrine tumor (NET) associated with von Hippel\u2013Lindau syndrome (VHL). Pancreas 41:492\u2013493. https:\/\/doi.org\/10.1097\/MPA.0b013e31822a645e","journal-title":"Pancreas"},{"key":"1905_CR82","first-page":"517","volume":"36","author":"A Babinska","year":"2015","unstructured":"Babinska A, Studniarek M, \u015awi\u0105tkowska-Stodulska R, Sworczak K (2015) Sunitinib treatment for multifocal renal cell carcinoma (RCC) and pancreatic neuroendocrine tumor (NET) in patient with von Hippel\u2013Lindau disease. Case report. Neuro Endocrinol Lett Neuro Endocrinol Lett 36:517\u2013520","journal-title":"Neuro Endocrinol Lett Neuro Endocrinol Lett"},{"key":"1905_CR83","doi-asserted-by":"publisher","first-page":"629","DOI":"10.2169\/internalmedicine.55.5796","volume":"55","author":"A Kobayashi","year":"2016","unstructured":"Kobayashi A, Takahashi M, Imai H, Akiyama S, Sugiyama S, Komine K, Saijo K, Takahashi M, Takahashi S, Shirota H, Sato N, Fujishima F, Shuin T, Shimodaira H, Ishioka C (2016) Attainment of a long-term favorable outcome by sunitinib treatment for pancreatic neuroendocrine tumor and renal cell carcinoma associated with von Hippel\u2013Lindau disease. Intern Med 55:629\u2013634. https:\/\/doi.org\/10.2169\/internalmedicine.55.5796","journal-title":"Intern Med"},{"key":"1905_CR84","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.2174\/092986711795471293","volume":"18","author":"MT Pirrotta","year":"2011","unstructured":"Pirrotta MT, Bernardeschi P, Fiorentini G (2011) Targeted-therapy in advanced renal cell carcinoma. Curr Med Chem 18:1651\u20131657. https:\/\/doi.org\/10.2174\/092986711795471293","journal-title":"Curr Med Chem"},{"key":"1905_CR85","doi-asserted-by":"publisher","first-page":"e271","DOI":"10.1111\/j.1755-3768.2009.01611.x","volume":"88","author":"W Wackernagel","year":"2010","unstructured":"Wackernagel W, Lackner EM, Pilz S, Mayer C, Stepan V (2010) Von Hippel\u2013Lindau disease: treatment of retinal haemangioblastomas by targeted therapy with systemic bevacizumab. Acta Ophthalmol 88:e271\u2013e272. https:\/\/doi.org\/10.1111\/j.1755-3768.2009.01611.x","journal-title":"Acta Ophthalmol"},{"key":"1905_CR86","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.2967\/jnumed.110.075002","volume":"51","author":"AR Haug","year":"2010","unstructured":"Haug AR, Auernhammer CJ, W\u00e4ngler B, Schmidt GP, Uebleis C, G\u00f6ke B, Cumming P, Bartenstein P, Tiling R, Hacker M (2010) 68Ga-DOTATATE PET\/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med 51:1349\u20131356. https:\/\/doi.org\/10.2967\/jnumed.110.075002","journal-title":"J Nucl Med"},{"key":"1905_CR87","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1007\/s00259-016-3421-6","volume":"43","author":"V Prasad","year":"2016","unstructured":"Prasad V, Tiling N, Denecke T, Brenner W, Pl\u00f6ckinger U (2016) Potential role of 68Ga-DOTATOC PET\/CT in screening for pancreatic neuroendocrine tumour in patients with von Hippel\u2013Lindau disease. Eur J Nucl Med Mol Imaging 43:2014\u20132020. https:\/\/doi.org\/10.1007\/s00259-016-3421-6","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1905_CR88","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.627672","volume":"12","author":"K Mowrey","year":"2021","unstructured":"Mowrey K, Northrup H, Rougeau P, Hashmi SS, Krueger DA, Ebrahimi-Fakhari D, Towbin AJ, Trout AT, Capal JK, Franz DN, Rodriguez-Buritica D (2021) Frequency, progression, and current management: report of 16 new cases of nonfunctional pancreatic neuroendocrine tumors in tuberous sclerosis complex and comparison with previous reports. Front Neurol 12:627672. https:\/\/doi.org\/10.3389\/fneur.2021.627672","journal-title":"Front Neurol"},{"key":"1905_CR89","unstructured":"Zamora EA, Aeddula NR (2022) Tuberous Sclerosis. In: StatPearls. Treasure Island (FL): StatPearls Publishing. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK538492\/"},{"key":"1905_CR90","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0185713","volume":"12","author":"C Rosset","year":"2017","unstructured":"Rosset C, Vairo F, Bandeira IC, Correia RL, de Goes FV, da Silva RTB, Bueno LSM, de Miranda Gomes MCS, Galv\u00e3o HCR, Neri JICF, Achatz MI, Netto CBO, Ashton-Prolla P (2017) Molecular analysis of TSC1 and TSC2 genes and phenotypic correlations in Brazilian families with tuberous sclerosis. PLoS ONE 12:e0185713. https:\/\/doi.org\/10.1371\/journal.pone.0185713","journal-title":"PLoS ONE"},{"key":"1905_CR91","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1677\/ERC-08-0142","volume":"16","author":"D Dworakowska","year":"2009","unstructured":"Dworakowska D, Grossman AB (2009) Are neuroendocrine tumours a feature of tuberous sclerosis? A systematic review. Endocr Relat Cancer 16:45\u201358. https:\/\/doi.org\/10.1677\/ERC-08-0142","journal-title":"Endocr Relat Cancer"},{"key":"1905_CR92","doi-asserted-by":"publisher","first-page":"109","DOI":"10.4158\/EP.8.2.109","volume":"8","author":"MS Eledrisi","year":"2002","unstructured":"Eledrisi MS, Stuart CA, Alshanti M (2002) Insulinoma in a patient with tuberous sclerosis: is there an association? Endocr Pract 8:109\u2013112. https:\/\/doi.org\/10.4158\/EP.8.2.109","journal-title":"Endocr Pract"},{"key":"1905_CR93","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1002\/ajmg.a.62850","volume":"188","author":"LM Evans","year":"2022","unstructured":"Evans LM, Geenen KR, O\u2019Shea A, Hedgire SS, Ferrone CR, Thiele EA (2022) Tuberous sclerosis complex-associated nonfunctional pancreatic neuroendocrine tumors: management and surgical outcomes. Am J Med Genet A 188:2666\u20132671. https:\/\/doi.org\/10.1002\/ajmg.a.62850","journal-title":"Am J Med Genet A"},{"key":"1905_CR94","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00247-016-3701-0","volume":"47","author":"G Koc","year":"2017","unstructured":"Koc G, Sugimoto S, Kuperman R, Kammen BF, Karakas SP (2017) Pancreatic tumors in children and young adults with tuberous sclerosis complex. Pediatr Radiol 47:39\u201345. https:\/\/doi.org\/10.1007\/s00247-016-3701-0","journal-title":"Pediatr Radiol"},{"issue":"6","key":"1905_CR95","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/j.1399-0004.2011.01805.x","volume":"82","author":"AM Larson","year":"2012","unstructured":"Larson AM, Hedgire SS, Deshpande V, Stemmer-Rachamimov AO, Harisinghani MG, Ferrone CR, Shah U, Thiele EA et al (2012) Pancreatic neuroendocrine tumors in patients with tuberous sclerosis complex. Clin Genet 82(6):558\u2013563","journal-title":"Clin Genet"},{"key":"1905_CR96","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s12022-017-9497-0","volume":"29","author":"DL Kolin","year":"2018","unstructured":"Kolin DL, Duan K, Ngan B, Gerstle JT, Krzyzanowska MK, Somers GR, Mete O (2018) Expanding the spectrum of colonic manifestations in tuberous sclerosis: L-cell neuroendocrine tumor arising in the background of rectal PEComa. Endocr Pathol 29:21\u201326. https:\/\/doi.org\/10.1007\/s12022-017-9497-0","journal-title":"Endocr Pathol"},{"key":"1905_CR97","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/PAS.0b013e31823d0560","volume":"36","author":"NC Arva","year":"2012","unstructured":"Arva NC, Pappas JG, Bhatla T, Raetz EA, Macari M, Ginsburg HB, Hajdu CH (2012) Well-differentiated pancreatic neuroendocrine carcinoma in tuberous sclerosis\u2013case report and review of the literature. Am J Surg Pathol 36:149\u2013153. https:\/\/doi.org\/10.1097\/PAS.0b013e31823d0560","journal-title":"Am J Surg Pathol"},{"key":"1905_CR98","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1097\/00000478-200310000-00012","volume":"27","author":"P Francalanci","year":"2003","unstructured":"Francalanci P, Diomedi-Camassei F, Purificato C, Santorelli FM, Giannotti A, Dominici C, Inserra A, Boldrini R (2003) Malignant pancreatic endocrine tumor in a child with tuberous sclerosis. Am J Surg Pathol 27:1386\u20131389. https:\/\/doi.org\/10.1097\/00000478-200310000-00012","journal-title":"Am J Surg Pathol"},{"key":"1905_CR99","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s004310051073","volume":"158","author":"S Verhoef","year":"1999","unstructured":"Verhoef S, van Diemen-Steenvoorde R, Akkersdijk WL, Bax NM, Ariyurek Y, Hermans CJ, van Nieuwenhuizen O, Nikkels PG, Lindhout D, Halley DJ, Lips K, van den Ouweland AM (1999) Malignant pancreatic tumour within the spectrum of tuberous sclerosis complex in childhood. Eur J Pediatr 158:284\u2013287. https:\/\/doi.org\/10.1007\/s004310051073","journal-title":"Eur J Pediatr"},{"key":"1905_CR100","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2018-227292","volume":"12","author":"JMV Amarjothi","year":"2019","unstructured":"Amarjothi JMV, Jesudason J, Ramasamy V, Babu OLN (2019) Interesting pancreatic tumour in the background of tuberous sclerosis. BMJ Case Reports 12:e227292. https:\/\/doi.org\/10.1136\/bcr-2018-227292","journal-title":"BMJ Case Reports"},{"key":"1905_CR101","doi-asserted-by":"publisher","first-page":"747","DOI":"10.3390\/ijms19030747","volume":"19","author":"G Lamberti","year":"2018","unstructured":"Lamberti G, Brighi N, Maggio I, Manuzzi L, Peterle C, Ambrosini V, Ricci C, Casadei R, Campana D (2018) The role of mTOR in neuroendocrine tumors: future cornerstone of a winning strategy? Int J Mol Sci 19:747. https:\/\/doi.org\/10.3390\/ijms19030747","journal-title":"Int J Mol Sci"},{"key":"1905_CR102","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/iju.13390","volume":"24","author":"M Wataya-Kaneda","year":"2017","unstructured":"Wataya-Kaneda M, Uemura M, Fujita K, Hirata H, Osuga K, Kagitani-Shimono K, Nonomura N, Tuberous Sclerosis Complex Board of Osaka University Hospital (2017) Tuberous sclerosis complex: recent advances in manifestations and therapy. Int J Urol 24:681\u2013691. https:\/\/doi.org\/10.1111\/iju.13390","journal-title":"Int J Urol"},{"key":"1905_CR103","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1200\/JCO.2007.13.6374","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, Hess K, Ng C, Abbruzzese JL, Ajani JA (2008) Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 26:1316\u20131323. https:\/\/doi.org\/10.1200\/JCO.2007.13.6374","journal-title":"J Clin Oncol"},{"key":"1905_CR104","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1517\/21678707.2016.1127158","volume":"4","author":"R Moavero","year":"2016","unstructured":"Moavero R, Graziola F, Romagnoli G, Curatolo P (2016) Toward targeted treatments in tuberous sclerosis. Expert Opin Orphan Drugs 4:243\u2013253. https:\/\/doi.org\/10.1517\/21678707.2016.1127158","journal-title":"Expert Opin Orphan Drugs"},{"key":"1905_CR105","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1093\/annonc\/mdx007","volume":"28","author":"J Schrader","year":"2017","unstructured":"Schrader J, Henes FO, Perez D, Burdak-Rothkamm S, Stein A, Izbicki JR, Lohse AW (2017) Successful mTOR inhibitor therapy for a metastastic neuroendocrine tumour in a patient with a germline TSC2 mutation. Ann Oncol 28:904\u2013905. https:\/\/doi.org\/10.1093\/annonc\/mdx007","journal-title":"Ann Oncol"},{"key":"1905_CR106","doi-asserted-by":"publisher","first-page":"7263","DOI":"10.3748\/wjg.v26.i45.7263","volume":"26","author":"N Ishida","year":"2020","unstructured":"Ishida N, Miyazu T, Tamura S, Suzuki S, Tani S, Yamade M, Iwaizumi M, Osawa S, Hamaya Y, Shinmura K, Sugimura H, Miura K, Furuta T, Sugimoto K (2020) Tuberous sclerosis patient with neuroendocrine carcinoma of the esophagogastric junction: a case report. World J Gastroenterol 26:7263\u20137271. https:\/\/doi.org\/10.3748\/wjg.v26.i45.7263","journal-title":"World J Gastroenterol"},{"key":"1905_CR107","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/ajmg.a.33139","volume":"152A","author":"DG Evans","year":"2010","unstructured":"Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, Lalloo F (2010) Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A 152A:327\u2013332. https:\/\/doi.org\/10.1002\/ajmg.a.33139","journal-title":"Am J Med Genet A"},{"key":"1905_CR108","first-page":"6","volume":"44","author":"DE Goldgar","year":"1989","unstructured":"Goldgar DE, Green P, Parry DM, Mulvihill JJ (1989) Multipoint linkage analysis in neurofibromatosis type 1: an international collaboration. Am J Hum Genet 44:6\u201312","journal-title":"Am J Hum Genet"},{"key":"1905_CR109","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1399-0004.2006.00639.x","volume":"70","author":"AB Trov\u00f3-Marqui","year":"2006","unstructured":"Trov\u00f3-Marqui AB, Tajara EH (2006) Neurofibromin: a general outlook. Clin Genet 70:1\u201313. https:\/\/doi.org\/10.1111\/j.1399-0004.2006.00639.x","journal-title":"Clin Genet"},{"key":"1905_CR110","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1002\/cncr.23648","volume":"113","author":"RT Jensen","year":"2008","unstructured":"Jensen RT, Berna MJ, Bingham DB, Norton JA (2008) Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer 113:1807\u20131843. https:\/\/doi.org\/10.1002\/cncr.23648","journal-title":"Cancer"},{"key":"1905_CR111","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/S1474-4422(07)70075-3","volume":"6","author":"RE Ferner","year":"2007","unstructured":"Ferner RE (2007) Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective. Lancet Neurol 6:340\u2013351. https:\/\/doi.org\/10.1016\/S1474-4422(07)70075-3","journal-title":"Lancet Neurol"},{"key":"1905_CR112","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1086\/320121","volume":"68","author":"SA Rasmussen","year":"2001","unstructured":"Rasmussen SA, Yang Q, Friedman JM (2001) Mortality in neurofibromatosis 1: an analysis using US death certificates. Am J Hum Genet 68:1110\u20131118. https:\/\/doi.org\/10.1086\/320121","journal-title":"Am J Hum Genet"},{"key":"1905_CR113","doi-asserted-by":"publisher","first-page":"559","DOI":"10.21037\/jgo.2020.03.09","volume":"11","author":"JL Geurts","year":"2020","unstructured":"Geurts JL (2020) Inherited syndromes involving pancreatic neuroendocrine tumors. J Gastrointest Oncol 11:559\u2013566. https:\/\/doi.org\/10.21037\/jgo.2020.03.09","journal-title":"J Gastrointest Oncol"},{"key":"1905_CR114","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.anchir.2005.12.005","volume":"131","author":"R Caiazzo","year":"2006","unstructured":"Caiazzo R, Mariette C, Piessen G, Jany T, Carnaille B, Triboulet JP (2006) Type I neurofibromatosis, pheochromocytoma and somatostatinoma of the ampulla. Literature review. Ann Chir 131:393\u2013397","journal-title":"Ann Chir"},{"key":"1905_CR115","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1136\/bmj.285.6355.1618","volume":"285","author":"AM Cantor","year":"1982","unstructured":"Cantor AM, Rigby CC, Beck PR, Mangion D (1982) Neurofibromatosis phaeochromocytoma, and somatostatinoma. Br Med J (Clin Res Ed) 285:1618\u20131619. https:\/\/doi.org\/10.1136\/bmj.285.6355.1618","journal-title":"Br Med J (Clin Res Ed)"},{"key":"1905_CR116","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1007\/s11605-009-1123-0","volume":"14","author":"D Relles","year":"2010","unstructured":"Relles D, Baek J, Witkiewicz A, Yeo CJ (2010) Periampullary and duodenal neoplasms in neurofibromatosis type 1: two cases and an updated 20-year review of the literature yielding 76 cases. J Gastrointest Surg 14:1052\u20131061. https:\/\/doi.org\/10.1007\/s11605-009-1123-0","journal-title":"J Gastrointest Surg"},{"key":"1905_CR117","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/1097-0142(19900401)65:7<1591::aid-cncr2820650723>3.0.co;2-n","volume":"65","author":"AP Burke","year":"1990","unstructured":"Burke AP, Sobin LH, Shekitka KM, Federspiel BH, Helwig EB (1990) Somatostatin-producing duodenal carcinoids in patients with von Recklinghausen\u2019s neurofibromatosis. A predilection for black patients. Cancer 65:1591\u20131595. https:\/\/doi.org\/10.1002\/1097-0142(19900401)65:7%3c1591::aid-cncr2820650723%3e3.0.co;2-n","journal-title":"Cancer"},{"key":"1905_CR118","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1007\/s40618-021-01528-1","volume":"44","author":"RE Rossi","year":"2021","unstructured":"Rossi RE, Milanetto AC, Andreasi V, Campana D, Coppa J, Nappo G et al (2021) Risk of preoperative understaging of duodenal neuroendocrine neoplasms: a plea for caution in the treatment strategy. J Endocrinol Invest 44:2227\u20132234. https:\/\/doi.org\/10.1007\/s40618-021-01528-1","journal-title":"J Endocrinol Invest"},{"key":"1905_CR119","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1210\/jc.2018-01074","volume":"103","author":"ML Gild","year":"2018","unstructured":"Gild ML, Tsang V, Samra J, Clifton-Bligh RJ, Tacon L, Gill AJ (2018) Hypercalcemia in glucagon cell hyperplasia and neoplasia (Mahvash syndrome): a new association. J Clin Endocrinol Metab 103:3119\u20133123. https:\/\/doi.org\/10.1210\/jc.2018-01074","journal-title":"J Clin Endocrinol Metab"},{"key":"1905_CR120","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1097\/MPA.0000000000001044","volume":"47","author":"R Yu","year":"2018","unstructured":"Yu R (2018) Mahvash disease 10 years after discovery. Pancreas 47:511\u2013515. https:\/\/doi.org\/10.1097\/MPA.0000000000001044","journal-title":"Pancreas"},{"key":"1905_CR121","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2217\/ije-2016-0005","volume":"3","author":"J Rhyu","year":"2016","unstructured":"Rhyu J, Yu R (2016) Mahvash disease: an autosomal recessive hereditary pancreatic neuroendocrine tumor syndrome. Inter J Endocrine Oncol 3:235\u2013243. https:\/\/doi.org\/10.2217\/ije-2016-0005","journal-title":"Inter J Endocrine Oncol"},{"key":"1905_CR122","doi-asserted-by":"publisher","first-page":"E783","DOI":"10.1210\/jc.2014-4405","volume":"100","author":"B Sipos","year":"2015","unstructured":"Sipos B, Sperveslage J, Anlauf M, Hoffmeister M, Henopp T, Buch S, Hampe J, Weber A, Hammel P, Couvelard A, H\u00f6bling W, Lieb W, Boehm BO, Kl\u00f6ppel G (2015) Glucagon cell hyperplasia and neoplasia with and without glucagon receptor mutations. J Clin Endocrinol Metab 100:E783\u2013E788. https:\/\/doi.org\/10.1210\/jc.2014-4405","journal-title":"J Clin Endocrinol Metab"},{"key":"1905_CR123","doi-asserted-by":"publisher","unstructured":"Tang L, Yu R (2016) A novel hereditary pancreatic neuroendocrine tumor syndrome associated with biallelic inactivation of the glucagon receptor. In: Abstracts of the 13th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease. March 9\u201311, 2016, Barcelona, Spain: Abstracts. Neuroendocrinology 103 Suppl 1:1\u2013128. https:\/\/doi.org\/10.1159\/000448725","DOI":"10.1159\/000448725"},{"key":"1905_CR124","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1530\/EDM-16-0081","volume":"2016","author":"E Larger","year":"2016","unstructured":"Larger E, Wewer Albrechtsen NJ, Hansen LH, Gelling RW, Capeau J, Deacon CF, Madsen OD, Yakushiji F, De Meyts P, Holst JJ, Nishimura E (2016) Pancreatic \u03b1-cell hyperplasia and hyperglucagonemia due to a glucagon receptor splice mutation. Endocrinol Diabetes Metab Case Rep 2016:16\u20130081. https:\/\/doi.org\/10.1530\/EDM-16-0081","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"1905_CR125","doi-asserted-by":"publisher","first-page":"253","DOI":"10.4166\/kjg.2014.63.4.253","volume":"63","author":"H Kang","year":"2014","unstructured":"Kang H, Kim S, Lim TS, Lee HW, Choi H, Kang CM, Kim HG, Bang S (2014) A case of alpha-cell nesidioblastosis and hyperplasia with multiple glucagon-producing endocrine cell tumor of the pancreas. Korean J Gastroenterol 63:253\u2013257. https:\/\/doi.org\/10.4166\/kjg.2014.63.4.253","journal-title":"Korean J Gastroenterol"},{"key":"1905_CR126","doi-asserted-by":"publisher","first-page":"S1193","DOI":"10.14309\/01.ajg.0000785052.64085.6a","volume":"116","author":"J Robbins","year":"2021","unstructured":"Robbins J, DiMeglio M, Halegoua-DeMarzio D (2021) S2880 Mahvash disease: a case of recurrent liver failure in the setting of octreotide administration. Am J Gastroenterol 116:S1193\u2013S1194. https:\/\/doi.org\/10.14309\/01.ajg.0000785052.64085.6a","journal-title":"Am J Gastroenterol"},{"key":"1905_CR127","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1530\/JME-12-0051","volume":"49","author":"R Yu","year":"2012","unstructured":"Yu R, Chen CR, Liu X, Kodra JT (2012) Rescue of a pathogenic mutant human glucagon receptor by pharmacological chaperones. J Mol Endocrinol 49:69\u201378. https:\/\/doi.org\/10.1530\/JME-12-0051","journal-title":"J Mol Endocrinol"},{"key":"1905_CR128","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.622693","volume":"12","author":"JY Lim","year":"2021","unstructured":"Lim JY, Pommier RF (2021) Clinical features, management, and molecular characteristics of familial small bowel neuroendocrine tumors. Front Endocrinol (Lausanne) 12:622693. https:\/\/doi.org\/10.3389\/fendo.2021.622693","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1905_CR129","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.dld.2016.10.007","volume":"49","author":"L de Mestier","year":"2017","unstructured":"de Mestier L, Pasmant E, Fleury C, Brixi H, Sohier P, F\u00e9ron T, Diebold MD, Clauser E, Cadiot G, Groupe d\u2019\u00c9tude des Tumeurs Endocrines (2017) Familial small-intestine carcinoids: chromosomal alterations and germline inositol polyphosphate multikinase sequencing. Dig Liver Dis 49:98\u2013102. https:\/\/doi.org\/10.1016\/j.dld.2016.10.007","journal-title":"Dig Liver Dis"},{"key":"1905_CR130","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1053\/j.gastro.2015.04.008","volume":"149","author":"Y Sei","year":"2015","unstructured":"Sei Y, Zhao X, Forbes J, Szymczak S, Li Q, Trivedi A et al (2015) A hereditary form of small intestinal carcinoid associated with a germline mutation in inositol polyphosphate multikinase. Gastroenterology 149:67\u201378. https:\/\/doi.org\/10.1053\/j.gastro.2015.04.008","journal-title":"Gastroenterology"},{"key":"1905_CR131","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.surg.2015.05.041","volume":"159","author":"MS Hughes","year":"2016","unstructured":"Hughes MS, Azoury SC, Assadipour Y, Straughan DM, Trivedi AN, Lim RM, Joy G, Voellinger MT, Tang DM, Venkatesan AM, Chen CC, Louie A, Quezado MM, Forbes J, Wank SA (2016) Prospective evaluation and treatment of familial carcinoid small intestine neuroendocrine tumors (SI-NETs). Surgery 159:350\u2013356. https:\/\/doi.org\/10.1016\/j.surg.2015.05.041","journal-title":"Surgery"},{"key":"1905_CR132","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1097\/JTO.0b013e3181861d7b","volume":"3","author":"E Lim","year":"2008","unstructured":"Lim E, Goldstraw P, Nicholson AG, Travis WD, Jett JR, Ferolla P, Bomanji J, Rusch VW, Asamura H, Skogseid B, Baudin E, Caplin M, Kwekkeboom D, Brambilla E, Crowley J (2008) Proceedings of the IASLC international workshop on advances in pulmonary neuroendocrine tumors 2007. J Thorac Oncol 3:1194\u20131201. https:\/\/doi.org\/10.1097\/JTO.0b013e3181861d7b","journal-title":"J Thorac Oncol"},{"key":"1905_CR133","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.21873\/anticanres.12349","volume":"38","author":"D Moris","year":"2018","unstructured":"Moris D, Ntanasis-Stathopoulos I, Tsilimigras DI, Vagios S, Karamitros A, Karaolanis G, Griniatsos J, Papalampros A, Papaconstantinou I, Glantzounis GK, Spartalis E, Blazer DG 3rd, Felekouras E (2018) Update on surgical management of small bowel neuroendocrine tumors. Anticancer Res 38:1267\u20131278. https:\/\/doi.org\/10.21873\/anticanres.12349","journal-title":"Anticancer Res"},{"key":"1905_CR134","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.3390\/cancers11091395","volume":"11","author":"V Larouche","year":"2019","unstructured":"Larouche V, Akirov A, Alshehri S, Ezzat S (2019) Management of small bowel neuroendocrine tumors. Cancers (Basel) 11:1395. https:\/\/doi.org\/10.3390\/cancers11091395","journal-title":"Cancers (Basel)"},{"key":"1905_CR135","doi-asserted-by":"publisher","first-page":"534","DOI":"10.4158\/EP14464.DSC","volume":"21","author":"EH Liu","year":"2015","unstructured":"Liu EH, Solorzano CC, Katznelson L, Vinik AI, Wong R, Randolph G (2015) AACE\/ACE disease state clinical review: diagnosis and management of midgut carcinoids. Endocr Pract 21:534\u2013545. https:\/\/doi.org\/10.4158\/EP14464.DSC","journal-title":"Endocr Pract"},{"key":"1905_CR136","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1055\/s-0038-1642054","volume":"31","author":"RM Byrne","year":"2018","unstructured":"Byrne RM, Pommier RF (2018) Small bowel and colorectal carcinoids. Clin Colon Rectal Surg 31:301\u2013308. https:\/\/doi.org\/10.1055\/s-0038-1642054","journal-title":"Clin Colon Rectal Surg"},{"key":"1905_CR137","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.bpg.2012.12.002","volume":"26","author":"J Strosberg","year":"2012","unstructured":"Strosberg J (2012) Neuroendocrine tumours of the small intestine. Best Pract Res Clin Gastroenterol 26:755\u2013773. https:\/\/doi.org\/10.1016\/j.bpg.2012.12.002","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"1905_CR138","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1530\/ERC-15-0490","volume":"23","author":"ME Caplin","year":"2016","unstructured":"Caplin ME, Pavel M, \u0106wik\u0142a JB, Phan AT, Raderer M, Sedl\u00e1\u010dkov\u00e1 E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Gomez-Panzani E, Ruszniewski P, Investigators CLARINET (2016) Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study. Endocr Relat Cancer 23:191\u2013199. https:\/\/doi.org\/10.1530\/ERC-15-0490","journal-title":"Endocr Relat Cancer"},{"key":"1905_CR139","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1200\/JCO.2007.15.9020","volume":"26","author":"MH Kulke","year":"2008","unstructured":"Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs CS (2008) Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 26:3403\u20133410. https:\/\/doi.org\/10.1200\/JCO.2007.15.9020","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"1905_CR140","doi-asserted-by":"publisher","first-page":"4504","DOI":"10.1200\/jco.2007.25.18_suppl.4504","volume":"25","author":"TJ Hobday","year":"2007","unstructured":"Hobday TJ, Rubin J, Holen K, Picus J, Donehower R, Marschke R et al (2007) MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): A phase II Consortium (P2C) study. J Clin Oncol 25(18 suppl):4504","journal-title":"J Clin Oncol"},{"key":"1905_CR141","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1097\/MPA.0b013e3181ec1380","volume":"39","author":"AT Phan","year":"2010","unstructured":"Phan AT, Oberg K, Choi J, Harrison LH Jr, Hassan MM, Strosberg JR, Krenning EP, Kocha W, Woltering EA, Maples WJ, North American Neuroendocrine Tumor Society (NANETS) (2010) NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus). Pancreas 39:784\u2013798. https:\/\/doi.org\/10.1097\/MPA.0b013e3181ec1380","journal-title":"Pancreas"},{"key":"1905_CR142","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1093\/annonc\/mdv252","volume":"26","author":"E Grande","year":"2015","unstructured":"Grande E, Capdevila J, Castellano D, Teul\u00e9 A, Dur\u00e1n I, Fuster J et al (2015) Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE). Ann Oncol 26:1987\u20131993. https:\/\/doi.org\/10.1093\/annonc\/mdv252","journal-title":"Ann Oncol"},{"key":"1905_CR143","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/PAS.0b013e3181874eca","volume":"33","author":"M Anlauf","year":"2009","unstructured":"Anlauf M, Bauersfeld J, Raffel A, Koch CA, Henopp T, Alkatout I et al (2009) Insulinomatosis: a multicentric insulinoma disease that frequently causes early recurrent hyperinsulinemic hypoglycemia. Am J Surg Pathol 33:339\u2013346. https:\/\/doi.org\/10.1097\/PAS.0b013e3181874eca","journal-title":"Am J Surg Pathol"},{"key":"1905_CR144","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109813","volume":"37","author":"EM Walker","year":"2021","unstructured":"Walker EM, Cha J, Tong X, Guo M, Liu JH, Yu S, Iacovazzo D, Mauvais-Jarvis F, Flanagan SE, Korbonits M, Stafford J, Jacobson DA, Stein R (2021) Sex-biased islet \u03b2 cell dysfunction is caused by the MODY MAFA S64F variant by inducing premature aging and senescence in males. Cell Rep 37:109813. https:\/\/doi.org\/10.1016\/j.celrep.2021.109813","journal-title":"Cell Rep"},{"key":"1905_CR145","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1073\/pnas.1712262115","volume":"115","author":"D Iacovazzo","year":"2018","unstructured":"Iacovazzo D, Flanagan SE, Walker E, Quezado R, de Sousa Barros FA, Caswell R et al (2018) MAFA missense mutation causes familial insulinomatosis and diabetes mellitus. Proc Natl Acad Sci U S A 115:1027\u20131032. https:\/\/doi.org\/10.1073\/pnas.1712262115","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1905_CR146","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.3390\/cancers14071798","volume":"14","author":"C Fottner","year":"2022","unstructured":"Fottner C, Sollfrank S, Ghiasi M, Adenaeuer A, Musholt T, Schad A, Miederer M, Schadmand-Fischer S, Weber MM, Lackner KJ, Rossmann H (2022) Second MAFA variant causing a phosphorylation defect in the transactivation domain and familial insulinomatosis. Cancers (Basel) 14:1798. https:\/\/doi.org\/10.3390\/cancers14071798","journal-title":"Cancers (Basel)"},{"key":"1905_CR147","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/jdi.13180","volume":"11","author":"Y Yamada","year":"2020","unstructured":"Yamada Y, Kitayama K, Oyachi M, Higuchi S, Kawakita R, Kanamori Y, Yorifuji T (2020) Nationwide survey of endogenous hyperinsulinemic hypoglycemia in Japan (2017\u20132018): Congenital hyperinsulinism, insulinoma, non-insulinoma pancreatogenous hypoglycemia syndrome and insulin autoimmune syndrome (Hirata\u2019s disease). J Diabetes Investig 11:554\u2013563. https:\/\/doi.org\/10.1111\/jdi.13180","journal-title":"J Diabetes Investig"},{"key":"1905_CR148","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1097\/MPA.0000000000001933","volume":"50","author":"I Mintziras","year":"2021","unstructured":"Mintziras I, Peer K, Goerlach J, Goebel JN, Ramaswamy A, Slater EP, Kann PH, Bartsch DK (2021) Adult proinsulinomatosis associated with a MAFA germline mutation as a rare cause of recurrent hypoglycemia. Pancreas 50:1450\u20131453. https:\/\/doi.org\/10.1097\/MPA.0000000000001933","journal-title":"Pancreas"},{"key":"1905_CR149","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1111\/cen.13480","volume":"87","author":"L Ye","year":"2017","unstructured":"Ye L, Wang W, Ospina NS, Jiang L, Christakis I, Lu J, Zhou Y, Zhu W, Cao Y, Wang S, Perrier ND, Young WF Jr, Ning G, Wang W (2017) Clinical features and prognosis of thymic neuroendocrine tumours associated with multiple endocrine neoplasia type 1: a single-centre study, systematic review and meta-analysis. Clin Endocrinol (Oxf) 87:706\u2013716. https:\/\/doi.org\/10.1111\/cen.13480","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1905_CR150","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3390\/cancers14030520","volume":"14","author":"M Araujo-Castro","year":"2022","unstructured":"Araujo-Castro M, Pascual-Corrales E, Molina-Cerrillo J, Moreno Mata N, Alonso-Gordoa T (2022) Bronchial carcinoids: from molecular background to treatment approach. Cancers 14:520. https:\/\/doi.org\/10.3390\/cancers14030520","journal-title":"Cancers"},{"key":"1905_CR151","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.3390\/ijms2208404","volume":"22","author":"F Marini","year":"2021","unstructured":"Marini F, Giusti F, Tonelli F, Brandi ML (2021) Pancreatic neuroendocrine neoplasms in multiple endocrine neoplasia type 1. Int J Mol Sci 22:4041. https:\/\/doi.org\/10.3390\/ijms2208404","journal-title":"Int J Mol Sci"},{"key":"1905_CR152","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s12672-015-0228-z","volume":"6","author":"N Singh Ospina","year":"2015","unstructured":"Singh Ospina N, Thompson GB, Nichols FC, Cassivi SD, Young WF (2015) Thymic and bronchial carcinoid tumors in multiple endocrine neoplasia type 1: the Mayo Clinic experience from 1977 to 2013. Horm Cancer 6:247\u2013253. https:\/\/doi.org\/10.1007\/s12672-015-0228-z","journal-title":"Horm Cancer"},{"key":"1905_CR153","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1159\/000435921","volume":"103","author":"DK Bartsch","year":"2016","unstructured":"Bartsch DK, Albers MB, Lopez CL, Apitzsch JC, Walthers EM, Fink L, Fendrich V, Slater EP, Waldmann J, Anlauf M (2016) Bronchopulmonary neuroendocrine neoplasms and their precursor lesions in multiple endocrine neoplasia type 1. Neuroendocrinology 103:240\u2013247. https:\/\/doi.org\/10.1159\/000435921","journal-title":"Neuroendocrinology"},{"key":"1905_CR154","doi-asserted-by":"publisher","first-page":"e1014","DOI":"10.1210\/clinem\/dgaa800","volume":"106","author":"MFM van den Broek","year":"2021","unstructured":"van den Broek MFM, de Laat JM, van Leeuwaarde RS, van de Ven AC, de Herder WW, Dekkers OM, Drent ML, Kerstens MN, Bisschop PH, Havekes B, Hackeng WM, Brosens LAA, Vriens MR, Buikhuisen WA, Valk GD (2021) The management of neuroendocrine tumors of the lung in MEN1: results from the Dutch MEN1 Study Group. J Clin Endocrinol Metab 106:e1014\u2013e1027. https:\/\/doi.org\/10.1210\/clinem\/dgaa800","journal-title":"J Clin Endocrinol Metab"},{"key":"1905_CR155","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00268-017-4135-z","volume":"42","author":"P Lecomte","year":"2018","unstructured":"Lecomte P, Binquet C, le Bras M, Tabarin A, Cardot-Bauters C, Borson-Chazot F et al (2018) Histologically proven bronchial neuroendocrine tumors in MEN1: a GTE 51-case cohort study. World J Surg 42:143\u2013152. https:\/\/doi.org\/10.1007\/s00268-017-4135-z","journal-title":"World J Surg"},{"key":"1905_CR156","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/cncr.20825","volume":"103","author":"N Sachithanandan","year":"2005","unstructured":"Sachithanandan N, Harle RA, Burgess JR (2005) Bronchopulmonary carcinoid in multiple endocrine neoplasia type 1. Cancer 103:509\u2013515. https:\/\/doi.org\/10.1002\/cncr.20825","journal-title":"Cancer"},{"key":"1905_CR157","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1053\/j.semdp.2019.03.002","volume":"36","author":"J Guilmette","year":"2019","unstructured":"Guilmette J, Nos\u00e9 V (2019) Paraneoplastic syndromes and other systemic disorders associated with neuroendocrine neoplasms. Semin Diagn Pathol 36:229\u2013239. https:\/\/doi.org\/10.1053\/j.semdp.2019.03.002","journal-title":"Semin Diagn Pathol"},{"key":"1905_CR158","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s11154-022-09719-8","volume":"23","author":"RM Ruggeri","year":"2022","unstructured":"Ruggeri RM, Altieri B, Grossrubatcher E, Minotta R, Tarsitano MG, Zamponi V, Isidori AM, Faggiano A, Colao AM, NIKE Group (2022) Sex differences in carcinoid syndrome: a gap to be closed. Rev Endocr Metab Disord 23:659\u2013669. https:\/\/doi.org\/10.1007\/s11154-022-09719-8","journal-title":"Rev Endocr Metab Disord"},{"key":"1905_CR159","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1159\/000484984","volume":"95","author":"EMBP Reuling","year":"2018","unstructured":"Reuling EMBP, Dickhoff C, Plaisier PW, Coup\u00e9 VMH, Mazairac AHA, Lely RJ, Bonjer HJ, Daniels JMA (2018) Endobronchial treatment for bronchial carcinoid: patient selection and predictors of outcome. Respiration 95:220\u2013227. https:\/\/doi.org\/10.1159\/000484984","journal-title":"Respiration"},{"key":"1905_CR160","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.cllc.2020.12.004","volume":"22","author":"N Prinzi","year":"2021","unstructured":"Prinzi N, Rossi RE, Proto C, Leuzzi G, Raimondi A, Torchio M et al (2021) Recent advances in the management of typical and atypical lung carcinoids. Clin Lung Cancer 22:161\u2013169. https:\/\/doi.org\/10.1016\/j.cllc.2020.12.004","journal-title":"Clin Lung Cancer"},{"key":"1905_CR161","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/S1470-2045(17)30681-2","volume":"18","author":"P Ferolla","year":"2017","unstructured":"Ferolla P, Brizzi MP, Meyer T, Mansoor W, Mazieres J, do Cao C, et al (2017) Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol 18:1652\u20131664. https:\/\/doi.org\/10.1016\/S1470-2045(17)30681-2","journal-title":"Lancet Oncol"},{"key":"1905_CR162","doi-asserted-by":"publisher","first-page":"693","DOI":"10.6004\/jnccn.2018.0056","volume":"16","author":"MH Shah","year":"2018","unstructured":"Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, Halperin D et al (2018) NCCN guidelines insights: neuroendocrine and adrenal tumors, version 2.2018. J Natl Compr Canc Netw 16:693\u2013702. https:\/\/doi.org\/10.6004\/jnccn.2018.0056","journal-title":"J Natl Compr Canc Netw"},{"key":"1905_CR163","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00259-015-3190-7","volume":"43","author":"A Mariniello","year":"2016","unstructured":"Mariniello A, Bodei L, Tinelli C, Baio SM, Gilardi L, Colandrea M, Papi S, Valmadre G, Fazio N, Galetta D, Paganelli G, Grana CM (2016) Long-term results of PRRT in advanced bronchopulmonary carcinoid. Eur J Nucl Med Mol Imaging 43:441\u2013452. https:\/\/doi.org\/10.1007\/s00259-015-3190-7","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1905_CR164","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/cas.13427","volume":"109","author":"N Fazio","year":"2018","unstructured":"Fazio N, Buzzoni R, Delle Fave G, Tesselaar ME, Wolin E, van Cutsem E et al (2018) Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis. Cancer Sci 109:174\u2013181. https:\/\/doi.org\/10.1111\/cas.13427","journal-title":"Cancer Sci"},{"key":"1905_CR165","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/j.1365-2265.2012.04467.x","volume":"78","author":"A Sakurai","year":"2013","unstructured":"Sakurai A, Imai T, Kikumori T, Horiuchi K, Okamoto T, Uchino S, Kosugi S, Suzuki S, Suyama K, Yamazaki M, Sato A, MEN Consortium of Japan (2013) Thymic neuroendocrine tumour in multiple endocrine neoplasia type 1: female patients are not rare exceptions. Clin Endocrinol (Oxf) 78:248\u2013254. https:\/\/doi.org\/10.1111\/j.1365-2265.2012.04467.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1905_CR166","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1210\/jc.2014-1560","volume":"99","author":"JM de Laat","year":"2014","unstructured":"de Laat JM, Pieterman CR, van den Broek MF, Twisk JW, Hermus AR, Dekkers OM, de Herder WW, van der Horst-Schrivers AN, Drent ML, Bisschop PH, Havekes B, Vriens MR, Valk GD (2014) Natural course and survival of neuroendocrine tumors of thymus and lung in MEN1 patients. J Clin Endocrinol Metab 99:3325\u20133333. https:\/\/doi.org\/10.1210\/jc.2014-1560","journal-title":"J Clin Endocrinol Metab"},{"key":"1905_CR167","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s12672-016-0269-y","volume":"7","author":"I Christakis","year":"2016","unstructured":"Christakis I, Qiu W, Silva Figueroa AM, Hyde S, Cote GJ, Busaidy NL, Williams M, Grubbs E, Lee JE, Perrier ND (2016) Clinical features, treatments, and outcomes of patients with thymic carcinoids and multiple endocrine neoplasia type 1 syndrome at MD Anderson Cancer Center. Horm Cancer 7:279\u2013287. https:\/\/doi.org\/10.1007\/s12672-016-0269-y","journal-title":"Horm Cancer"},{"key":"1905_CR168","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00268-009-0290-1","volume":"34","author":"P Goudet","year":"2010","unstructured":"Goudet P, Murat A, Binquet C, Cardot-Bauters C, Costa A, Ruszniewski P et al (2010) Risk factors and causes of death in men1 disease. a gte (Groupe D\u2019etude des Tumeurs Endocrines) cohort study among 758 patients. World J Surg 34:249\u2013255. https:\/\/doi.org\/10.1007\/s00268-009-0290-1","journal-title":"World J Surg"},{"key":"1905_CR169","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/MD.0b013e3182954af1","volume":"92","author":"T Ito","year":"2013","unstructured":"Ito T, Igarashi H, Uehara H, Berna MJ, Jensen RT (2013) Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1\/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors. Medicine (Baltimore) 92:135\u2013181. https:\/\/doi.org\/10.1097\/MD.0b013e3182954af1","journal-title":"Medicine (Baltimore)"},{"key":"1905_CR170","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1080\/14737140.2022.2052278","volume":"22","author":"Y Muto","year":"2022","unstructured":"Muto Y, Okuma Y (2022) Therapeutic options in thymomas and thymic carcinomas. Expert Rev Anticancer Ther 22:401\u2013413. https:\/\/doi.org\/10.1080\/14737140.2022.2052278","journal-title":"Expert Rev Anticancer Ther"},{"key":"1905_CR171","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3390\/cancers14030775","volume":"14","author":"H Watanabe","year":"2022","unstructured":"Watanabe H, Fujishima F, Komoto I, Imamura M, Hijioka S, Hara K et al (2022) Somatostatin receptor 2 expression profiles and their correlation with the efficacy of somatostatin analogues in gastrointestinal neuroendocrine tumors. Cancers (Basel) 14:775. https:\/\/doi.org\/10.3390\/cancers14030775","journal-title":"Cancers (Basel)"},{"key":"1905_CR172","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s12253-018-0426-4","volume":"25","author":"A Zalatnai","year":"2019","unstructured":"Zalatnai A, Galambos E, Perj\u00e9si E (2019) Importance of immunohistochemical detection of somatostatin receptors. Pathol Oncol Res 25:521\u2013525. https:\/\/doi.org\/10.1007\/s12253-018-0426-4","journal-title":"Pathol Oncol Res"},{"key":"1905_CR173","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001281","volume":"94","author":"S Mehta","year":"2015","unstructured":"Mehta S, de Reuver PR, Gill P, Andrici J, D\u2019Urso L, Mittal A, Pavlakis N, Clarke S, Samra JS, Gill AJ (2015) Somatostatin receptor SSTR-2a expression is a stronger predictor for survival Than Ki-67 in pancreatic neuroendocrine tumors. Medicine (Baltimore) 94:e1281. https:\/\/doi.org\/10.1097\/MD.0000000000001281","journal-title":"Medicine (Baltimore)"},{"key":"1905_CR174","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1097\/MPA.0000000000000700","volume":"45","author":"ZR Qian","year":"2016","unstructured":"Qian ZR, Li T, Ter-Minassian M, Yang J, Chan JA, Brais LK et al (2016) Association between somatostatin receptor expression and clinical outcomes in neuroendocrine tumors. Pancreas 45:1386\u20131393. https:\/\/doi.org\/10.1097\/MPA.0000000000000700","journal-title":"Pancreas"},{"key":"1905_CR175","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/modpathol.3800954","volume":"20","author":"M Volante","year":"2007","unstructured":"Volante M, Brizzi MP, Faggiano A, La Rosa S, Rapa I, Ferrero A, Mansueto G, Righi L, Garancini S, Capella C, De Rosa G, Dogliotti L, Colao A, Papotti M (2007) Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol 20:1172\u20131182. https:\/\/doi.org\/10.1038\/modpathol.3800954","journal-title":"Mod Pathol"},{"key":"1905_CR176","doi-asserted-by":"publisher","first-page":"e2056","DOI":"10.1210\/clinem\/dgab891","volume":"107","author":"C Mennetrey","year":"2022","unstructured":"Mennetrey C, le Bras M, Bando-Delaunay A, Al-Mansour L, Haissaguerre M, Batisse-Lignier M et al (2022) Value of somatostatin receptor PET\/CT in patients with MEN1 at various stages of their disease. J Clin Endocrinol Metab 107:e2056\u2013e2064. https:\/\/doi.org\/10.1210\/clinem\/dgab891","journal-title":"J Clin Endocrinol Metab"},{"key":"1905_CR177","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1136\/gutjnl-2020-322595","volume":"71","author":"WM Hackeng","year":"2022","unstructured":"Hackeng WM, Brosens LAA, Kim JY, O\u2019Sullivan R, Sung YN, Liu TC et al (2022) Non-functional pancreatic neuroendocrine tumours: ATRX\/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX\/PDX1 expression and tumour size. Gut 71:961\u2013973. https:\/\/doi.org\/10.1136\/gutjnl-2020-322595","journal-title":"Gut"},{"key":"1905_CR178","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","volume":"33","author":"G Rindi","year":"2022","unstructured":"Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LAA, Ezzat S, de Herder WW, Klimstra DS, Papotti M, Asa SL (2022) Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr Pathol 33:115\u2013154. https:\/\/doi.org\/10.1007\/s12022-022-09708-2","journal-title":"Endocr Pathol"},{"key":"1905_CR179","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1158\/1078-0432.CCR-08-1476","volume":"15","author":"MH Kulke","year":"2009","unstructured":"Kulke MH, Hornick JL, Frauenhoffer C, Hooshmand S, Ryan DP, Enzinger PC, Meyerhardt JA, Clark JW, Stuart K, Fuchs CS, Redston MS (2009) O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 15:338\u2013345. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-1476","journal-title":"Clin Cancer Res"},{"key":"1905_CR180","doi-asserted-by":"publisher","first-page":"837","DOI":"10.3727\/096504021X16214197880808","volume":"28","author":"R della Monica","year":"2022","unstructured":"della Monica R, Cuomo M, Visconti R, di Mauro A, Buonaiuto M, Costabile D et al (2022) Evaluation of MGMT gene methylation in neuroendocrine neoplasms. Oncol Res 28:837\u2013845. https:\/\/doi.org\/10.3727\/096504021X16214197880808","journal-title":"Oncol Res"},{"key":"1905_CR181","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/annonc\/mdw561.)","volume":"28","author":"S Faivre","year":"2017","unstructured":"Faivre S, Niccoli P, Castellano D, Valle JW, Hammel P, Raoul JL et al (2017) Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study. Ann Oncol 28:339\u2013343. https:\/\/doi.org\/10.1093\/annonc\/mdw561.)","journal-title":"Ann Oncol"},{"key":"1905_CR182","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1007\/s12020-021-02942-4","volume":"76","author":"G Puliani","year":"2022","unstructured":"Puliani G, Sesti F, Anastasi E, Verrico M, Tarsitano MG, Feola T et al (2022) Angiogenic factors as prognostic markers in neuroendocrine neoplasms. Endocrine 76:208\u2013217. https:\/\/doi.org\/10.1007\/s12020-021-02942-4","journal-title":"Endocrine"}],"updated-by":[{"DOI":"10.1007\/s40618-022-01924-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000}}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-022-01905-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-022-01905-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-022-01905-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T00:18:56Z","timestamp":1674260336000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-022-01905-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,30]]},"references-count":182,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["1905"],"URL":"https:\/\/doi.org\/10.1007\/s40618-022-01905-4","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40618-022-01924-1","asserted-by":"object"}]},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,30]]},"assertion":[{"value":"30 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40618-022-01924-1","URL":"https:\/\/doi.org\/10.1007\/s40618-022-01924-1","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no financial or non-financial competing interests to disclose<b>.<\/b>","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors have no ethical conflict to disclose. The study was performed in accordance with the principles of the Declaration of Helsinki. Local Ethics Research Committee approval was obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from the patients for publication of this case series.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"No animals were used for this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}}]}}